The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion
- PMID: 26462021
- PMCID: PMC4747410
- DOI: 10.18632/oncotarget.5534
The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion
Abstract
Objective: This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.
Methods: 217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.
Results: Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.
Conclusions: Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.
Keywords: CD4+CD25+ T lymphocyte; adoptive cell therapy; early stage breast cancer; prognosis; triple negative breast cancer.
Conflict of interest statement
There are none.
Figures



Similar articles
-
Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study.Cytotherapy. 2018 Jan;20(1):126-133. doi: 10.1016/j.jcyt.2017.08.018. Epub 2017 Oct 4. Cytotherapy. 2018. PMID: 28988693
-
Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.Oncotarget. 2017 Feb 28;8(9):15610-15620. doi: 10.18632/oncotarget.14779. Oncotarget. 2017. PMID: 28121628 Free PMC article.
-
Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.Asian Pac J Cancer Prev. 2015;16(6):2419-23. doi: 10.7314/apjcp.2015.16.6.2419. Asian Pac J Cancer Prev. 2015. PMID: 25824775
-
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1. Breast Cancer Res Treat. 2014. PMID: 25361613 Review.
-
The dawn of immunotherapy for breast cancer.Clin Adv Hematol Oncol. 2019 Jun;17(6):332-335. Clin Adv Hematol Oncol. 2019. PMID: 31437135 Review. No abstract available.
Cited by
-
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.Chin J Cancer Res. 2018 Jun;30(3):315-326. doi: 10.21147/j.issn.1000-9604.2018.03.04. Chin J Cancer Res. 2018. PMID: 30046226 Free PMC article.
-
A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine.Oncol Lett. 2018 Jul;16(1):529-535. doi: 10.3892/ol.2018.8631. Epub 2018 May 4. Oncol Lett. 2018. PMID: 29928442 Free PMC article.
-
Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.Am J Transl Res. 2020 Jul 15;12(7):3940-3952. eCollection 2020. Am J Transl Res. 2020. PMID: 32774747 Free PMC article.
-
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017. Oncoimmunology. 2016. PMID: 28507788 Free PMC article.
-
A Neutrophil Extracellular Traps Signature Predicts the Clinical Outcomes and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.Front Mol Biosci. 2022 Feb 18;9:833771. doi: 10.3389/fmolb.2022.833771. eCollection 2022. Front Mol Biosci. 2022. PMID: 35252353 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 26/01/2015.
-
- Choudhury A, Palma M, Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clinical lung cancer. 2008;1:S37–44. - PubMed
-
- Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, Shi FD, Ljunggren HG, Bai XF. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. Journal of leukocyte biology. 2006;80:1345–1353. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials